Table 4.

Noncancer drug repurposing candidates for dual inhibition of DNMT and HDAC.

Drug	Approved for	Epigenetic Target	Cancer Model
Berberine	Parasitic and fungal infections	HDAC class I, II, IV and DNMT1, DNMT3A	Prostate Cancer [98], Multiple Myeloma [99], Lung Cancer [100]
Parthenolide	Anti-inflammatory (not approved)	HDAC1 and DNMT	Breast Cancer [101,102], Leukemia [103], Myeloma [104], Colon Cancer [102]
Resveratrol	Natural Compound (not approved)	HDAC and DNMT1	Nonsmall Cell Lung Cancer [105], Breast Cancer [106,107], Thyroid Cancer [108]